Mariner’s Compass Therapeutics CMPX Stock Holding History

Mariner’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,381	Closed	-$21.6K	–	3517
2025 Q1	$21.6K	Sell	11,381 -9,292	-45%	-$24.7K	﹤0.01%	3371
2024 Q4	$30K	Buy	+20,673	New	+$34.3K	﹤0.01%	3332

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mariner's CMPX Position: Q2 2025 in Review

Mariner sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 11,381 shares — an estimated $21.6K sold.

Mariner first reported a position in CMPX in Q4 2024 and held it in 2 quarters. The position peaked at $30K in Q4 2024. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

Mariner reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
Mariner sold 11,381 Compass Therapeutics shares in Q2 2025, an estimated $21.6K.
Mariner first reported a position in Compass Therapeutics in Q4 2024 and held it in 2 quarters.
Mariner's Compass Therapeutics position peaked at $30K in Q4 2024.
103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on Mariner's 13F filing for Q2 2025, filed 14 Aug 2025.